Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets

Francisco M. Franco, Darin E. Jones, Peter K.W. Harris, Zhenfu Han, Scott A. Wildman, Cassie M. Jarvis, James W. Janetka

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Hepatocyte growth factor activator (HGFA), matriptase and hepsin are all S1 trypsin-like serine endopeptidases. HGFA is a plasma protease while hepsin and matriptase are type II transmembrane proteases (TTSPs). Upregulated expression and activity of all three proteases is associated with aberrant cancer cell signaling through c-MET and RON tyrosine kinase cell-signaling pathways in cancer. We modeled known benzamidine protease inhibitor scaffolds into the active sites of matriptase, hepsin and HGFA to design new non-peptide inhibitors of hepsin and HGFA. First, we used a docking model of the irreversible inhibitor, Nafamostat, bound to the active site of HGFA in order to explore structure activity relationships (SAR). Compounds were screened for inhibition of HGFA activity in a kinetic enzyme assay using a chromogenic substrate. Next, we designed matched pair compound libraries of 3-amidino and 4-amidino phenylalanine (benzamidine) arginine peptidomimetics based on the structure of matriptase inhibitor, CJ-672. Compounds were screened for inhibition of HGFA, matriptase, and hepsin enzyme activity using fluorogenic substrates. Using this strategy we have discovered the first reported non-peptide small molecule inhibitors of both HGFA and hepsin. These inhibitors have differential potency and selectivity towards all three proteases. A subset of piperazinyl ureas highlighted by 25a, have excellent potency and selectivity for hepsin over matriptase and HGFA.

Original languageEnglish
Pages (from-to)2328-2343
Number of pages16
JournalBioorganic and Medicinal Chemistry
Volume23
Issue number10
DOIs
StatePublished - May 15 2015

Keywords

  • Benzamidine
  • Cancer
  • Cell-signaling
  • Enzyme inhibitor
  • Growth factor
  • HGF
  • HGFA
  • Hepsin
  • MSP
  • Matriptase
  • Peptidomimetic
  • RON
  • Receptor tyrosine kinase
  • Serine protease
  • Small-molecule
  • Structure-based drug design
  • Therapeutic
  • c-MET

Fingerprint

Dive into the research topics of 'Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets'. Together they form a unique fingerprint.

Cite this